-
Thematic Analysis
NewRNA-Based Drugs and the Impact of COVID-19
This report investigates the past, current and future landscape of RNA-Based drugs, and how the success of the COVID-19 vaccines may have impacted this. High level analysis of the key trends and movements within the pharmaceutical industry in reference to RNA technology is provided, allowing you to identify and discern the key points within this area.
-
Product Insights
NewCutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Cutaneous Squamous Cell Carcinoma (cSCC) Clinical Trial Report Overview A total of 161 cSCC clinical trials were conducted as of February 2024. The cSCC clinical trial report provides a comprehensive understanding of the Cutaneous Squamous Cell Carcinoma clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·       ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RG-6341 in Chronic Cough
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RG-6341 in Chronic Cough report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RG-6341 in Chronic Cough Drug Details: RG-6341 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tazemetostat Hydrobromide in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tazemetostat Hydrobromide in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tazemetostat Hydrobromide in Marginal Zone B-cell Lymphoma Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisocabtagene Maraleucel in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisocabtagene Maraleucel in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisocabtagene Maraleucel in Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tuspetinib in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tuspetinib in Refractory Acute Myeloid Leukemia Drug Details: Tuspetinib (HM-43239) is under development for the...
-
Product Insights
Keloids – Drugs In Development, 2023
Global Markets Direct’s, ‘Keloids - Drugs In Development, 2023’, provides an overview of the Keloids pipeline landscape. The report provides comprehensive information on the therapeutics under development for Keloids, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Hemochromatosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemochromatosis - Drugs In Development, 2023’, provides an overview of the Hemochromatosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemochromatosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib in Pancreatic Cancer Drug Details: Olaparib (Lynparza) is an antineoplastic...
-
Product Insights
Hypertrophic Scars – Drugs In Development, 2023
Global Markets Direct’s, ‘Hypertrophic Scars - Drugs In Development, 2023’, provides an overview of the Hypertrophic Scars pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hypertrophic Scars, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...